Pharmacological treatment of traumatic brain injury: A review of agents in development

CNS Drugs

Volumn 15, Issue 7, 2001, Pages 553-581

  Hatton, J ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOPTOSIS INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; GROWTH FACTOR; STEM CELL FACTOR;

APOPTOSIS; BRAIN INJURY; CELL DAMAGE; HUMAN; INFLAMMATION; NECROSIS; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; REVIEW; STANDARDIZATION; TREATMENT PLANNING;

EID: 0034909297     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115070-00005     Document Type: Review

References (164)

1. Rehabilitation of persons with traumatic brain injury
2. The European Brain Injury Consortium survey of head injuries
3. Experimental drug therapies for head injury
4. Current status of neuroprotection trials for traumatic brain injury: Lessons from animal models and clinical studies
5. Craniocerebral trauma: Protection and retrieval of the neuronal population after injury
6. Jugular venous desaturation and outcome after head injury
7. Early and late systemic hypotension as a frequent and fundamental source of cerebral ischemia following severe brain injury in the Traumatic Coma Data Bank
8. The effect of nutritional support on outcome of severe head injury
9. Apoptosis: Overview and signal transduction pathways
10. Management and prognosis of severe traumatic brain injury: Part I guidelines for the management of severe traumatic brain injury
11. Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: A systematic review
12. EBIC-guidelines for management of severe head injury in adults: European Brain Injury Consortium
13. Corticosteroids in acute traumatic brain injury: Systematic review of randomised controlled trials
14. Prophylactic antiepileptic agents after head injury: A systematic review
15. Prevention of secondary ischemic insults after severe head injury
16. Effects of pegorgotein on neurologic outcome of patients with severe head injury
17. Failure of the competitive N-methyl-D-aspartate antagonist selfotel (CGS 19755) in the treatment of severe head injury: Results of two phase III clinical trials
18. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations
19. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury
20. Pitfalls and advances from the international tirilazad trial in moderate and severe head injury
21. Management and prognosis of severe traumatic brain injury. Part II: Early indicators of prognosis in severe traumatic brain injury
22. Conduct of head injury trials in the United States: The American Brain Injury Consortium (ABIC)
23. Clinical trials in head injury
24. Clinical trials in traumatic brain injury: What can we learn from previous studies?
25. Cerestat and other NMDA antagonists in ischemic stroke
26. Cerebral ischemia-reperfusion injury and adhesion
27. Cytokines and reperfusion injury
28. Reducing calcium overload in the ischemic brain
29. Neurotoxicity of excitatory amino acids
30. Effects of the N-methyl-D-aspartate receptor blocker MK-801 on neurologic function after experimental brain injury
31. Apoptosis: Definition, mechanisms, and relevance to disease
32. Caspase pathways, neuronal apoptosis, and CNS injury
33. Bcl-2 family gene products in cerebral ischemia and traumatic brain injury
34. Eicosanoids in the central nervous system
35. Increased plasma and ventricular fluid interleukin 6 levels in patients with head injury
36. Intrathecal and serum interleukin 6 and the acute phase response in patients with severe traumatic brain injuries
37. Interleukin 6 and interleukin 10 in cerebrospinal fluid after severe traumatic brain injury in children
38. Experimental brain injury induces expression of interleukin-1beta mRNA in the rat brain
39. Closed head injury triggers early production of TNF alpha and IL6 by brain tissue
40. Concomitant cortical expression of TNF-alpha and IL-1beta mRNAs follows early response gene expression in transient focal ischemia
41. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury
42. Cytokines in brain ischemia - The role of TNF alpha
43. Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment
44. Cytokines, inflammation, and brain injury: Role of tumor necrosis factor-alpha
45. Closed head injury triggers early production on TNF-alpha and IL-6 by brain tissue
46. Transcranial cytokine gradients in patients requiring intensive care after acute brain injury
47. Cytokines in the central nervous system: Regulatory roles in neuronal function, cell death and repair
48. Local infusion of interleukin 6 attenuates the neurotoxic effects of NMDA on rat striatal cholinergic neurons
49. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6
50. Involvement of cytokines in acute neurodegeneration in the CNS
51. Proliferation of astrocytes in vitro in response to cytokines
52. Induced expression of adhesion molecules following focal ischemia
53. Glutamate and the pathophysiology of hypoxic-ischemic brain damage
54. Neuroprotection in head injury
55. Channel blocking drugs for the NMDA receptor
56. Zinc supplementation is associated with improved neurologic recovery rate and visceral protein levels of patients with severe closed head injury
57. New pharmacologic strategies for acute neuronal injury
58. Opportunities for neuroprotective drugs in clinical management of head injury
59. A controlled cortical impact model of traumatic brain injury in the rat
60. The release and uptake of excitate amino acids
61. Noncompetitive NMDA receptor antagonists acting on the polyamine site
62. Strategies for neuroprotection with glutamate antagonists
63. Mitochondrial participation in ischemic and traumatic neural cell death
64. Neuronal apoptosis after CNS injury: The roles of glutamate and calcium
65. Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease
66. The neurochemical and metabolic cascade following brain injury: Moving from animal models to man
67. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury
68. Effect of cyclosporin A on behavioral outcome after severe brain injury in rats
69. Cyclosporin A improves learning after lateral fluid percussion injury in rats
70. Cyclosporin A significantly amerliorates cortical damage following experimental traumatic brain injury in rodents
71. Free radical pathways in CNS injury
72. Involvement of superoxide and xanthine oxidase with death due to cerebral ischemia-induced seizures in gerbils
73. Neuroprotective properties of nitric oxide
74. Peroxynitrite scavengers for the acute treatment of traumatic brain injury
75. Molecular strategies in CNS injury
76. Endogenous neuroprotection factors and traumatic brain injury: Mechanisms of action and implications for therapy
77. Alterations in BDNF and trkB mRNA levels in the cerebral cortex following experimental brain trauma in rats
78. Alterations in BDNF and NT-3 mRNAs in rat hippocampus after experimental brain trauma
79. Increase of insulin-like growth factor (IGF)-1, IGF binding protein-2 and -4 mRNAs following cerebral contusion
80. Protective and rescuing abilities of IGF-1 and some putative free radical scavengers against beta-amyloid-inducing toxicity in neurons
81. Intravenous insulin-like growth factor-I (IGF-1) in moderate-to-severe head injury: A phase II safety and efficacy trial
82. Pharmacological advance in the treatment of acute brain injury
83. The concept of combination therapy in acute ischemic stroke
84. Neuroprotection by the inhibition of apoptosis
85. Implication of poly(ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism
86. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia
87. Cerebral hemodynamic effects of phenylephrine and L-arginine after cortical impact injury
88. Rivastigmine, a brain selective ACEsterase inhibitor amcliorates cognitive and motor deficits induced by closed-head injury in the mouse
89. Post-injury administration of BIBN99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats
90. Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma
91. Significant reduction in brain swelling by administration of nonpeptide kinin B2 receptor antagonist LF 16-0687MS after controlled cortical impact injury in rats
92. Traumatic brain contusions: A clinical role for the kinin antagonist CP-0127
93. Effects of the bradykinin antagonist Bradycor (deltibant, CP-0127) in severe traumatic brain injury: Results of a multicenter, randomised, placebo-controlled trial
94. COX2 increases acutely and chronically in neurons and astrocytes following traumatic brain injury in the rat
95. Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury
96. Inhibition of cyclooxygenase 2 by numesulide decreases prostaglandin E2 formation but does not alter brain edema or clinical recovery after closed head injury in rats
97. Brain injury induces COX-2 gene expression: Inhibition by a PAF antagonist
98. Effect of prostacyclin on cortical lesion volume following experimental brain injury in the rat
99. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury
100. Pathological changes induced in cerebrocortical neurons by phenycyclidine and related drugs
101. Neuronal vacuolization and necrosis induced by the noncompetitive NMDA antagonists MK801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex
102. Neuroprotective effect of eliprodil: Attenuation of a conditioned freezing deficit induced by traumatic injury of the right parietal cortex in the rat
103. Effects of the novel NMDA antagonists CP-98,113, CP-101,581 and CP-101,606 on cognitive function and regional cerebral edema following experimental brain injury in the rat
104. An open-label study of CP-101,606 in subjects with a severe traumatic head injury of spontaneous intracerebral hemorrhage
105. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury
106. Clinical pharmacology of CNS 1102 in volunteers
107. The cerebral hemodynamic and metabolic effects of the noncompetitive NMDA antagonist CNS 1102 in humans with severe head injury
108. Investigational neuroprotective drugs in traumatic brain injury
109. Phase II studies of the glycine antagonist GV150526 in acute stroke: The North American experience
110. Effect of the novel high-affinity glycine-site N-methyl-D-aspartate antagonist ACEA- 1021 on 1125MK-801 binding after subdural hematoma in the rat: An in vivo autoradiographic study
111. The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat
112. Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride
113. The desglycinyl metabolite of remacemide hydrochloride is neuroprotective in cultured rat cortical neurons
114. Neuroprotective effects of the glutamate release inhibitor 629C89 in temporary middle cerebral artery occlusion
115. The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat
116. Blockade of NAALADase: A novel neuroprotective strategy based on limiting glutamate and elevating NAAG
117. Influence of LY 300164, an antagonist of AMPA/kainate receptors, on the anticonvulsant activity of clonazepam
118. Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration
119. Alterations in ionized and total blood magnesium after experimental traumatic brain injury: Relationship to neurobehavioral outcome and neuroprotective efficacy of magnesium chloride
120. Blood-free magnesium concentration declines following graded experimental traumatic brain injury
121. Brain free magnesium concentration is predictive of motor outcome following traumatic axonal brian injury in rats
122. Magnesium protects against neurological deficit after brain injury
123. Magnesium sulphate improves neurologic outcome following severe closed head injury in rats
124. Optimization of magnesium therapy after severe diffuse axonal brain injury in rats
125. Neuroprotective effects of MgSO4 and MgC12 in closed head injury: A comparative phosphorus NMR study
126. Increased mortality in female rats after severe diffuse traumatic brain injury is significantly attenuated by magnesium administration
127. Improved motor outcome in response to magnesium therapy received up to 24 hours after traumatic diffuse axonal brain injury in rats
128. Dose optimization of intravenous magnesium sulfate after acute stroke
129. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant
130. Development of HU-211 as a neuroprotectant for ischemic brain damage
131. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat
132. Clinical pharmacokinetics of escalating intravenous doses of dexabinol (HU-211), a neuroprotectant agent, in normal volunteers
133. Dexanabinol Pharmos
134. Dehydroepiandrosterone, pregnenolone and sex steroids down-regulate reactive astroglia in the male rat brain after a penetrating brain injury
135. Aromatase expression by astrocytes after brain injury: Implications for local estrogen formation in brain repair
136. Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: An in vitro model for assessment of the neuroprotective effects of estrogens
137. Nuclear estrogen receptor-independent neuroprotection by estratrienes: A novel interactions with glutathione
138. Estrogen improves biochemical and neurologic outcome following traumatic brain injury in male rats, but not in females
139. A multicenter trial of the efficacy of nimodipine on outcome after severe head injury
140. A randomised trial of nimodipine in severe head injury: HIT I: British/Finnish Cooperative Head Injury Trial Group
141. Nimodipine in traumatic subarachnoid haemorrhage: A re-analysis of the HIT I and HIT II trials
142. A double-blinded placebo controlled trial of the calcium entry blocking drug, nicardipine, in the treatment of vasospasm following severe head injury
143. Effects of an N-type calcium channel antagonist (SNX 111; ziconotide) on calcium-45 accumulation following fluid-percussion injury
144. New CNS-specific calcium antagonists
145. The novel compound LOE 908 attenuates acute neuromotor dysfunction but not cognitive impairment of cortical tissue loss following traumatic brain injury in rats
146. Ion channel modulation as the basis for neuroprotective action of MS-153
147. Blood-brain barrier breach following cortical contusion in the rat
148. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
149. FK506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin
150. Changes in the bioenergetic state of rat hippocampus during 2.5 minutes of ischemia and prevention of cell damage by cyclosporin A in hyperglycemic subjects
151. Amelioration by cyclosporin A of brain damage following 5 to 10 minutes of ischemia in rats subjected to preischemic hyperglycemia
152. Cyclosporin A protects against ischemia-reperfusion injury in the brain
153. A case of severe cerebral trauma in a patient under chronic treatment with cyclosporin A
154. Acute-phase response, interleukin-6 and alteration of cyclosporine pharmacokinetics
155. Antioxidant, OPC-14117, attenuates edema formation and behavioral deficits following cortical contusion in rats
156. Cerebroprotective effect of stable nitroxide radicals in closed head injury in the rat
157. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat
158. Lubeluzole following traumatic brain injury in the rat
159. The effect of human corticotrophin releasing factor on the formation of post-traumatic cerebral edema
160. Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats
161. Insulin-like growth factor-I (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury
162. Systemic and metabolic effects of insulin-like growth factor I and growth hormone in acute traumatic brain injury
163. Transplantation of neural progenitor and stem cells: Developmental insights may suggest new therapies for spinal cord and other CNS dysfunction
164. Responses of microglia and neural progenitors to mechanical brain injury